The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Outcome and prognostic markers in severe drug‐induced liver disease†
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The DILI fatality rate in our study was much lower than has been observed in other registries.
“It is therefore interesting that the DILI fatality rate in our study was much lower than has been observed in other registries 21,[23][24][25][26] .”
From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [24]
Approximately 10% of cases that fulfill Hy's law will progress to ALF.
“Studies have shown that approximately 10% of cases that fulfill Hy's law will progress to ALF [5,64], and is associated increased mortality or need for liver transplantation [65][66][67][68].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early indicators of prognosis in fulminant hepatic failure
O'Grady, J. G., Alexander, G. J. M., Hayllar, K. M., & Williams, R. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90081-4 · Cited by 2,085
Flagged first, then by citations
Research works printed but not linked: 25
- Bjørneboe, 1967, Infective hepatitis and toxic jaundice in a municipal hospital during a five‐year period: incidence and prognosis, Acta Med Scand, 182, 491, 10.1111/j.0954-6820.1967.tb10873.x · DOI
- Malchow‐Møller, 1981, Causes and characteristics of 500 consecutive causes of jaundice, Scand J Gastroenterol, 16, 1
- Whitehead, 2001, The causes of obvious jaundice in South West Wales: 2000, Gut, 48, 409, 10.1136/gut.48.3.409 · DOI
- Björnsson, 2003, Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis, Scand J Gastroenterol, 38, 86, 10.1080/00365520310000492 · DOI
- Ostapowicz, 2002, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States, Ann Intern Med, 137, 947, 10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
- Wei, 2004, Acute liver failure in Sweden: etiology and prognosis, Scand J Gastroenterol, 39, 48A
- Williams, 1996, Classification, etiology, and considerations of outcome in acute liver failure, Semin Liver Dis, 16, 343, 10.1055/s-2007-1007247 · DOI
- Hoofnagle, 1995, Fulminant hepatic failure: summary of a workshop, HEPATOLOGY, 21, 240
- Bakke, 1995, Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective, Clin Pharm Therap, 58, 108, 10.1016/0009-9236(95)90078-0 · DOI
- Zimmerman, 2000, Drug‐induced liver disease, Clin Liver Dis, 4, 73, 10.1016/S1089-3261(05)70097-0 · DOI · Paper page
- Black, 1975, Isoniazid‐associated hepatitis in 114 patients, Gastroenterology, 69, 289, 10.1016/S0016-5085(19)32568-5 · DOI
- Danan, 1993, Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug‐induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- Benichou, 1990, Criteria of drug‐induced liver disorders. Report of an International Consensus Meeting, J Hepatol, 11, 272, 10.1016/0168-8278(90)90124-A · DOI · Paper page
- Lee, 2000, Assessing causality in drug‐induced liver injury, J Hepatol, 33, 1003, 10.1016/S0168-8278(00)80136-1 · DOI
- Larrey, 2002, Epidemiology and individual susceptibility to adverse drug reactions affecting the liver, Semin Liver Dis, 22, 145, 10.1055/s-2002-30105 · DOI
- Kaplowitz, 2001, Drug‐induced liver disorders: implications for drug development and regulation, Drug Saf, 24, 483, 10.2165/00002018-200124070-00001 · DOI
- Sgro, 2002, Incidence of drug‐induced hepatic injuries: a French population‐based study, HEPATOLOGY, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
- Olsson, 2003, Drug‐induced hepatic injury in Sweden, HEPATOLOGY, 38, 531, 10.1053/jhep.2003.50284 · DOI
- Björnsson, 2004, Fulminant drug‐induced hepatic failure leading to death or liver transplantation in Sweden, Gastroenterology, 126, 1185A
- Olsson, 1992, Liver damage from flucloxacillin, cloxacillin and dicloxacillin, J Hepatol, 15, 154, 10.1016/0168-8278(92)90029-O · DOI
- Devereaux, 1995, Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?, Eur J Clin Pharmacol, 49, 81
- Fairley, 1993, Risk factors for development of flucloxacillin associated jaundice, BMJ, 306, 233, 10.1136/bmj.306.6872.233 · DOI
- McNeil, 1999, Postmarketing surveillance: strengths and limitations. The flucloxacillin‐dicloxacillin story, Med J Aust, 170, 270, 10.5694/j.1326-5377.1999.tb127751.x · DOI
- Ohmori, 2003, Clinical characteristics and prognostic indicators of drug‐induced fulminant hepatic failure, Hepato‐Gastroenterology, 50, 1531
- Gitlin, 1982, The serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis, Am J Gastroenterol, 77, 2
Cited by
Sorted by citations
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Bernal, W., & Wendon, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208937 · Cited by 1,169
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Stravitz, R. T., & Lee, W. M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31894-x · Cited by 844
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Andrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309
Acute Liver Failure Including Acetaminophen Overdose
Fontana, R. J. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.03.005 · Cited by 249
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Vorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172
Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability
Hendriks, D. F. G., Fredriksson Puigvert, L., Messner, S., Mortiz, W., & Ingelman-Sundberg, M. (2016) · Scientific Reports · doi:10.1038/srep35434 · Cited by 156
Sundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138
Self-citationDrug-induced liver injury: a clinical update
Ghabril, M., Chalasani, N., & Björnsson, E. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283383c7c · Cited by 123
Self-citationIntrahepatic cholestasis in common chronic liver diseases
Jüngst, C., Berg, T., Cheng, J., Green, R. M., Jia, J., Mason, A. L., & Lammert, F. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12128 · Cited by 82
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Rathi, C., Pipaliya, N., Patel, R., Ingle, M., Phadke, A., & Sawant, P. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0009.8600 · Cited by 61
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Inagaki, K., Mori, N., Honda, Y., Takaki, S., Tsuji, K., & Chayama, K. (2017) · Kanzo · doi:10.2957/kanzo.58.448 · Cited by 35
Abid, A., Subhani, F., Kayani, F., Awan, S., & Abid, S. (2020) · PLOS ONE · doi:10.1371/journal.pone.0231398 · Cited by 22
Metadata
- Authors
- Björnsson, E., & Olsson, R.
- Venue
- Hepatology
- Published
- 2005-08
- Volume
- 42
- Issue
- 2
- Pages
- 481-489
- ISSN
- 0270-9139
- Cited by
- 524
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
